Clinical Trial Detail

NCT ID NCT03048136
Title A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

non-small cell lung carcinoma

Therapies

Nivolumab + Ipilimumab

Age Groups: senior adult

Additional content available in CKB BOOST